Clinical Trials Logo

Neonatal Abstinence Syndrome clinical trials

View clinical trials related to Neonatal Abstinence Syndrome.

Filter by:

NCT ID: NCT03246243 Terminated - Hypoglycemia Clinical Trials

Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

Start date: March 29, 2017
Phase:
Study type: Observational

The main goal of this study is to quantitatively assess the sucking and feeding activity of infants at high risk of neurological impairment (preterm infants and term infants at risk of abnormal neurodevelopment) during oral sucking and feeding and correlate it with their underlying neurological impairment for the early diagnosis of brain injury.

NCT ID: NCT03134703 Terminated - Clinical trials for Neonatal Abstinence Syndrome

Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome

Start date: February 27, 2017
Phase: Phase 2
Study type: Interventional

This is a non-randomized, un-blinded feasibility study project comparing the Length of Stay (LOS) of Neonatal Intensive Care Unit (NICU) infants diagnosed with Neonatal Abstinence Syndrome (NAS) treated with methadone with historical data and a comparison group of NICU NAS infants treated with a different narcotic agent.

NCT ID: NCT03113656 Completed - Clinical trials for Neonatal Abstinence Syndrome

Weighted Blankets With Infants With NAS

Start date: July 14, 2017
Phase: N/A
Study type: Interventional

Infants with neonatal abstinence syndrome (NAS) who are cared for in a Neonatal Intensive Care Unit (NICU) often display symptoms including hyperactivity, irritability, jitteriness, poor feeding, and poor sleep patterns. The recommended first line of treatment to relieve these symptoms involves nonpharmacological interventions. The purpose of the current pilot study is to provide preliminary data to assist in the design of a larger scale study to examine one nonpharmacological intervention, weighted blankets. The pilot study will assess the feasibility of a cross-over randomized controlled design to study the impact of a weighted blanket on infants' symptoms of NAS. The aims of the study are: Aim1: To determine the feasibility of recruiting patients for a study evaluating the use of weighted blankets in the care of infants with NAS Aim 2: To determine the feasibility and safety of the study procedures Aim 3: To examine whether there is clinical benefit to using weighted blankets for the treatment of symptoms in infants with NAS. After informed consent is obtained, infants will be randomized to have either a weighted blanket or a non-weighted blanket placed on them first. A cross-over design will be used so all infants will experience both the non-weighted and weighted blankets. Thirty minutes before each feeding, baseline vital signs and Finnegan score will be obtained. Then, a blanket (weighted or non-weighted) will be placed on the infant for 30 minutes. Infants will be directly monitored and on heart rate/respiratory rate monitors while the blanket is applied. Vital signs and Finnegan scores will be obtained at the end of 30 minutes of blanket placement, infants will be fed, and vital signs and Finnegan scores will be obtained again 30 minutes after the blanket was removed. Descriptive statistics will be used to determine the enrollment rate and feasibility of the protocol. Nonparametric statistics will be used to compare total Finnegan scores for infants with the weighted blanket applied compared to infants with a non-weighted blanket applied. Changes in Finnegan scores will be examined to estimate an effect size to use in a power analysis for a future larger effectiveness study.

NCT ID: NCT03097484 Completed - Clinical trials for Neonatal Abstinence Syndrome

The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels

Start date: July 25, 2015
Phase: Phase 3
Study type: Interventional

Determine the effectiveness of lavender and chamomile aromatherapy of mitigation of symptoms of Neonatal Abstinence Syndrome

NCT ID: NCT03092011 Recruiting - Clinical trials for Neonatal Abstinence Syndrome

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

Start date: February 21, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether a medication, Clonidine can reduce the number of days a baby spends in the hospital and the number of days of medical treatment of withdrawal from Neonatal Abstinence Syndrome (NAS) as compared to Morphine Sulfate (used in routine care) .

NCT ID: NCT03028883 Completed - Clinical trials for Neonatal Abstinence Syndrome

Buprenorphine Dose Adjustments and Gestational Age

Start date: December 2, 2016
Phase: N/A
Study type: Observational

In this retrospective cohort study, we plan to examine the relationship between buprenorphine dose adjustments, gestational age, urine buprenorphine levels and the rate of neonatal abstinence syndrome in opioid-maintained pregnant women

NCT ID: NCT02872077 Completed - Clinical trials for Neonatal Abstinence Syndrome

Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome

AA NAS
Start date: August 2016
Phase: N/A
Study type: Interventional

This study will assess the efficacy of needle auricular acupuncture (AA) in neonatal abstinence syndrome (NAS) infants who require pharmacologic therapy at the Tampa General Hospital NICU. The investigators will evaluate efficacy of needle AA as an adjunct treatment for NAS by means of total methadone dose exposure, peak withdrawal scores, and overall length of stay. This is the first study to evaluate efficacy of needle AA as an adjunct treatment for NAS by means of total methadone dose exposure, peak withdrawal scores, and overall length of stay.

NCT ID: NCT02851303 Completed - Clinical trials for Neonatal Abstinence Syndrome

Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome

Start date: October 2016
Phase: Phase 4
Study type: Interventional

This study investigates the use of methadone versus morphine wean for the treatment of neonatal abstinence syndrome for infants exposed to opioids in utero. Half of infants who require pharmacotherapy for NAS will receive a methadone wean, and half will receive a morphine wean. Length of hospital stay, length of treatment and parent satisfaction will be studied.

NCT ID: NCT02810782 Completed - Clinical trials for Neonatal Abstinence Syndrome

How to Treat Opiate Withdrawal in Neonates

Start date: June 2001
Phase: Phase 3
Study type: Interventional

Three different drugs are used in a randomised, double blind, clinical multi-centre trial with three arms. Major objective is to investigate the duration of drug treatment based on the Finnegan score. Secondary objectives are to document weight gain, the need for adding a second drug when the first drug is not effective enough and possible side effects such as convulsions.

NCT ID: NCT02801331 Completed - Clinical trials for Neonatal Abstinence Syndrome

Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome

Start date: March 9, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the efficacy of a specially-constructed crib mattress that delivers gentle vibrations (stochastic vibrotactile stimulation) as a complementary, non-pharmacological intervention for treating drug withdrawal in newborns exposed to opioids in utero.